• Publications
  • Influence
Improved survival with ipilimumab in patients with metastatic melanoma.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associatedExpand
  • 10,248
  • 351
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
BACKGROUND Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibodyExpand
  • 7,973
  • 328
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
BACKGROUND Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycinExpand
  • 3,227
  • 166
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor,Expand
  • 1,805
  • 141
Inhibition of mutated, activated BRAF in metastatic melanoma.
BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targetedExpand
  • 3,134
  • 129
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advancedExpand
  • 2,887
  • 126
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600EExpand
  • 4,392
  • 115
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastaticExpand
  • 1,781
  • 112
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
BACKGROUND Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1Expand
  • 2,039
  • 68
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identifyExpand
  • 1,031
  • 65